Tratamento da doença de Alzheimer: avaliação crítica sobre o uso de anticolinesterásicos

Almeida, Osvaldo P.

doi:10.1590/s0004-282x1998000400029

Cited by 9 publications

(4 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Neurotransmitters also suffer alterations in AD with a decrease in the production of acetylcholine [96, 97] and the inactivation of acetylcholinesterase is the basis for AD medicine. On the other hand, recent data indicate that norepinephrine in the locus coeruleus seems to be associated with the protection of neurons during aging [98].…”

Section: Discussionmentioning

confidence: 99%

Theories of Aging and the Prevalence of Alzheimer’s Disease

Trevisan

Cristina-Pereira

Silva-Amaral

et al. 2019

BioMed Research International

View full text Add to dashboard Cite

Objective. Aging and AD are associated in some way, then it is reasonable to ask whether or not it is possible to age without AD inexorably appearing at any moment, depending on the period of life. Therefore, the goal of this review is to verify, in light of some aging theories, the prevalence of AD. Methods. For the purpose of this manuscript, the indexers Alzheimer, aging, Alzheimer, and aging were considered; theories of aging were researched. The research was conducted using PubMed, Medline, Scopus, Elsevier, and Google Scholar. Results. The most common subjects in the papers analyzed for this manuscript were aging and Alzheimer’s disease. The association between Alzheimer and theories of aging seems inconclusive. Conclusions. Accordingly, the general idea is that AD is associated with aging in such a way that almost all people will present this disease; however, it is plausible to consider that the increase in life expectancy will generate a high prevalence of AD. In a general sense, it seems that the theories of aging explain the origin of AD under superlative and catastrophic considerations and use more biomolecular data than social or behavioral data as the bases of analysis, which may be the problem.

show abstract

Section: Discussionmentioning

confidence: 99%

Theories of Aging and the Prevalence of Alzheimer’s Disease

Trevisan

Cristina-Pereira

Silva-Amaral

et al. 2019

BioMed Research International

View full text Add to dashboard Cite

show abstract

“…Donepezila é um medicamento inibidor reversível e seletivo de colinesterase, e que se mostrou eficaz no tratamento da Doença de Alzheimer em doses de 5 e 10 mg. O tratamento inicial é de 5 mg/ dia e a dose pose ser aumentada a partir da quarta semana para 10 mg/ dia. Esse medicamento apresenta vantagem quando comparados a outros da mesma classe, pois é administrado uma vez ao dia (Almeida, 1998).…”

Section: Tratamentounclassified

Atenção farmacêutica na Doença de Alzheimer

Rayanne

Veras

Leitão

2021

RSD

View full text Add to dashboard Cite

A Doença de Alzheimer (DA) é um distúrbio neurodegenerativo e principal causa de demência, pois a doença afeta inicialmente o hipocampo e progride lentamente para outras partes do cérebro, causando dano celular e morte, especificamente de neurônios, gerando danos irreversíveis e consequências para todo o funcionamento cognitivo, afetiva, intelectual e comportamental, influenciando negativamente na autonomia e independência do indivíduo. Os pacientes são submetidos a tratamentos de uso crônico, visto que não há cura para a doença de Alzheimer. O tratamento visa minimizar os sintomas da doença, possibilitando melhora parcial para prolongar a sobrevida e retardar a progressão. Dada a real importância da assistência farmacêutica dirigida ao paciente, que otimiza a resposta de uma determinada farmacoterapia, por meio da qual o farmacêutico juntamente com o paciente, realiza um plano de acompanhamento. Nesse contexto, este trabalho tem como objetivo salientar a importância da atenção farmacêutica tanto na farmacoterapia quanto fora da mesma. Trata-se de um estudo de revisão integrativa transversal e descritiva com abordagem qualitativa e quantitativa sobre o tema, onde foram feitas buscas nas bases de dados Scielo e BVS acerca do tema. Foram encontrados 1.199 trabalhos, no qual foi feita uma triagem para a coleta dos resultados. Foi observado que o tratamento da Doença de Alzheimer é capaz de retardar ou estagnar, temporariamente, o avanço dos sintomas visando aliviar os déficits cognitivos, as alterações de comportamento e melhorar a qualidade de vida do portador e de sua família. O tratamento da Doença de Alzheimer deve ser multidisciplinar e com o objetivo de propiciar a estabilização do comprometimento cognitivo, modificando as manifestações da doença, com um mínimo de efeitos adversos. Nesse contexto, os imunomoduladores têm maior probabilidade de se tornarem drogas capazes de influenciar o curso da DA, pois os estudos selecionados apresentaram melhor qualidade e os resultados foram promissores. Por outro lado, a toxicidade das drogas para o tratamento da DA constitui um grande obstáculo, e para contornar tal situação a presença da atenção farmacêutica se torna cada vez mais imprescindível.

show abstract

“…AChE inhibition becomes a promising therapeutic approach by propitiating a decrease in the rate of acetylcholine hydrolysis, causing an increase in acetylcholine activity in the synaptic cleft and a cognitive improvement with an increase in central cholinergic function [37]. In light of this, products from natural sources have proven attractive for studies aimed at the treatment of AD because they provide milder side effects at therapeutic doses and thus may contribute to overcoming limitations, high hepatoxicity, and low bioavailability of drugs that are already used in AD therapeutics [38,39].…”

Section: Grooming Numbermentioning

confidence: 99%

Essential Oil of <em>Lippia origanoides</em> H.B.K.: A Promising Compound Acetylcholinesterase Inhibitors for the Treatment of Alzheimer’s Disease

Rodrigues¹,

Santos²,

Machado³

et al. 2021

Preprint

View full text Add to dashboard Cite

Alzheimer's disease is characterized by a progressive decline of cognitive functions. The class of drugs used for the treatment are acetylcholinesterase inhibitors. Essential oils have contributed to folk medicine and discovery of new drugs for a long time. The purpose of the study was to investigate the in vitro and in silico the anti-acetylcholinesterase activity, as well as acute toxicity of the essential oil of Lippia origanoides. EOLO was obtained by hydrostelting and analyzed by gas chromatography-mass spectrometry. The inhibition assay of acetylcholinesterase enzyme activity was evaluated in vitro, as well as in silico by docking. The effects of EOLO on hematological, biochemical and behavioral parameters were analyzed in mices. We expose that EOLO shows good anti-acetylcholinesterase activity and low toxicity, possibly resulting from the action of the majority compounds thymol, carvacrol and p-cymene. The anti-acetylcholinesterase potential in vitro demonstrating a 70% inhibition. The docking results elucidated the participation of the major phenolics in AChE inhibition by interacting with the catalytic cavity of AchE. The acute oral toxicity test classified as low toxicity. These results contribute to expand the knowledge about essential oil of Lippia origanoides. Therefore, appears to be promising for herbal medicine production with anti-acetylcholinesterase and antioxidant activity.

show abstract

Tratamento da doença de Alzheimer: avaliação crítica sobre o uso de anticolinesterásicos

Cited by 9 publications

References 27 publications

Theories of Aging and the Prevalence of Alzheimer’s Disease

Theories of Aging and the Prevalence of Alzheimer’s Disease

Atenção farmacêutica na Doença de Alzheimer

Essential Oil of <em>Lippia origanoides</em> H.B.K.: A Promising Compound Acetylcholinesterase Inhibitors for the Treatment of Alzheimer’s Disease

Contact Info

Product

Resources

About